Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new sophistication. The management of chronic pain in general is now being broadly ...